50 WHO should continue to work with national and regional regulatory authorities to
coordinate and further integrate rules and mechanisms for approving and monitoring operation of pharmaceutical production facilities.
7. Promoting and sustaining financing mechanisms
Both the government of Member States and international donors should expand financing for promising neglected disease product development projects, including
for late-stage clinical trials and for new innovation-driven firms. Joint financing schemes like the existing collaboration between the Department of Biotechnology of
India and the Wellcome Trust are a promising way to channel international funding for health RD
8. Establishing monitoring and reporting systems
There is a need for improved information about ongoing initiatives to provide a stronger evidence base for policy analysis and recommendations. A methodical,
comprehensive, regularly updated and publicly accessible database of relevant initiatives is currently lacking but is badly needed in the current fragmented
landscape.
Start activities for the development of the Regional Health Observatory in a phased way in 3 steps, as recommended by the 2012 Report to the Secretariat, as follows: 1
research phase; 2 planning phase; and 3 pilot-testing phase. The Region should already start the research phase needs assessment and situational analysis for this
undertaking
The current tool available for the assessment of GSPA-PHI progress is relatively complicated and difficult to implement. There is a need to make the tool more user-
friendly to encourage more countries to use it. The experience of countries like Sri Lanka who have used the tool will be very useful inputs in simplifying it.
51
LIST OF REFERENCES
1. WHO. Intellectual property rights, innovation and public health. 56
th
World Health Assembly WHA56.27 28 May 2003.
http:www.apps.who.intgbarchivepdf.filesWHA56ea56r27.pdf 2. WHO. Public Health Innovation and Intellectual Property Rights Report of the Commission on
Intellectual Property Rights, Innovation and Public Health. Geneva: World Health Organization; April 2006.
3. WHO. Public health, innovation, essential health research and intellectual property rights: towards a global strategy and plan of action. 59
th
World Health Assembly WHA 59.24 27 May 2006
www.who.intphiRes59_R24-en.pdf 4. WHO. International trade and Health. 59
th
World Health Assembly WHA59.26 27 May 2006. www.who.intgbebwhapdf_filesA60A60_R26-en.pdf
5. WHO. Public Health Innovation and Intellectual Property. 60
th
World Health Assembly WHA60.30 24 May 2007.
www.who.intgbebwhapdf_filesWHA60A60_R30-en.pdf 6. WHO. Global strategy and plan of action on public health, innovation and intellectual
property. 61
st
World Health Assembly WHA 61.21 24 May 2008. www.who.intgbebwhapdf_filesA61A61_R21-en.pdf
7. WHO. Global strategy and plan of action on public health, innovation and intellectual property. 62
nd
World Health Assembly WHA 62.16 22 May 2009. www.who.intgbebwhapdf_filesA62
A62_R16-en.pdf 8. WHO. Establishment of a consultative working group on research and development:
financing and coordination. 63
rd
World Health Assembly WHA 63.28 21 May 2010. www.who.intphinewswha_A63_R28_en.pdf
9. WHO. Follow up of the report of the Consultative Working Group on Research and
Development: Financing and Coordination. 65
th
World Health Assembly WHA65.22 26 May 2012
www.who.intgbebwhapdf_filesWHA65A65A65_R22-en.pdf 10.
WHO. Follow up of the report of the Consultative Working Group on Research and Development: Financing and Coordination. EB13221 7 December 2012
www.who.intgbebwhapdf_filesEB132B132_21-en.pdf 11.
WHO. Follow up of the report of the Consultative Working Group on Research and Development: Financing and Coordination. 66
th
World Health Assembly WHA66.22 27 May 2013
www.who.intgbebwhapdf_filesWHA66A66_R22-en.pdf
